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Abstract
Background: Capecitabine is effective and indicated for the salvage treatment of metastatic breast cancer. Therefore, it is
essential to evaluate the efficacy of capecitabine in the adjuvant setting. There have been two large randomized studies to
determine whether patients with high-risk early breast cancer benefit from the addition of capecitabine to standard
chemotherapy, but they have yielded inconsistent results. We first undertook a meta-analysis to evaluate the efficacy of the
addition of capecitabine over standard treatment.
Methods: PubMed, EBSCO, Web of Science, conference proceedings and key trials were searched from 1998 to 2011. The
hazard ratio (HR) was used to evaluate the efficacy of a taxane-anthracycline regimen and a taxane-anthracycline-
capecitabine regimen in early breast cancer. All of the data from each study use either fixed-effects or random-effects by
Stata.
Findings: We found significant improvement in the additional capecitabine arm versus control in disease-free survival (DFS)
(HR=0.83, 95% CI: 0.71–0.98, P=0.027), overall survival (OS) (HR=0.71, 95% CI: 0.57–0.88, P=0.002), distant recurrence
(HR=0.79, 95% CI: 0.66–0.94, P=0.008) and the death from breast cancer only (HR=0.65, 95% CI: 0.51–0.83, P=0.001).
Meanwhile, the subgroup analysis revealed that capecitabine improved the DFS in triple negative (HR=0.71, 95% CI: 0.53–
0.96, P=0.028), hormone receptor negative (HR=0.73, CI: 0.56–0.94, P=0.017) and HER2 negative (HR=0.81, CI: 0.67–0.98,
P=0.034) patients.
Conclusion: Due to the synergistic effect of taxane and capecitabine, taxane-anthracycline-capecitabine regimen may
effectively improve the efficacy in the adjuvant setting and may be a novel generation of adjuvant chemotherapy regimen.
The results of the current meta-analysis support this hypothesis and indicate that taxane-based regimen with capecitabine
may be an effective, convenient, and well tolerated regimen in patients with early breast cancer.
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Introduction
The key milestones for breast cancer treatment were endocrine
therapy in the 1960s and polychemotherapy in the 1970s. In
recent decades, the development of effective targeted therapies has
been another significant milestone in breast cancer treatment [1].
As an adjuvant chemotherapy regimen, cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) combination chemother-
apy has achieved similar excellent efficacy as in the salvage setting
[2]. Anthracyclines appeared in 1972, followed by taxanes in the
1990s. Anthracycline- and taxane-based polychemotherapy regi-
mens have achieved better efficacy than any previous chemother-
apy regimen, so they have long been recommended as standard
adjuvant regimens in the main breast cancer treatment guidelines,
such as the National Comprehensive Cancer Network (NCCN)
guidelines and St Gallen Consensus. Based on data from large and
well-controlled clinical studies, gemcitabine, vinorelbine and
capecitabine have also entered clinical care as salvage treatment
for metastatic breast cancer. Unfortunately, some chemotherapy
drugs such as vinorelbine and gemcitabine have failed to show
superior efficacy in the adjuvant treatment, as the Finland
Herceptin Trial and tAnGo trial showed [3,4].
Capecitabine is a fluoropyrimidine carbamate, which is supplied
for oral administration as a systemic prodrug of 59-deoxy-5-
fluorouridine (59-DFUR). 59-DFUR is converted to 5-fluorouracil
by sequential enzyme activity. The enzyme responsible for the
final step is thymidine phosphorylase (TP), which is overexpressed
in breast cancer [5]. Some cytotoxic drugs such as docetaxel show
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increase the TP level in tumors [6]. Furthermore, capecitabine
combined with docetaxel has improved time to progression and
overall survival (OS) in some pivotal phase III trials [7]. For this
reason, the NCCN Breast Cancer Guidelines Committee decided
to incorporate docetaxel/capecitabine as a preferred combined
chemotherapy regimen for recurrent or metastatic breast cancer
[8].
Capecitabine is effective and indicated for the salvage treatment
of metastatic breast cancer. Therefore, it is essential to evaluate the
efficacy of capecitabine-containing regimens in the adjuvant
setting. To date, there have been two large randomized, open-
label, multicenter phase III studies to determine whether patients
with high-risk early breast cancer benefit from the addition of
capecitabine to standard chemotherapy, but they have yielded
inconsistent results. The Finxx trial suggested that addition of
capecitabine to a taxane–anthracycline regimen did not signifi-
cantly improve recurrence-free survival (HR=0.79, 95% CI:
0.60–1.04, P=0.087) or OS (HR=0.73, 95% CI: 0.52–1.04,
P=0.08) as compared to the taxane–anthracycline regimen. The
USON 01062 trial found significant improvement in OS
(HR=0.68, 95% CI: 0.51–0.92, P=0.011) rather than in
disease-free survival (DFS) (HR=0.84, 95% CI: 0.67–1.05,
P=0.125) in favor of capecitabine combined with a taxane–
anthracycline regimen [9,10,11].
For the above reasons, we sought to undertake a meta-analysis
to evaluate the efficacy of capecitabine when combined with
standard treatment in the adjuvant setting for early breast cancer.
We compared the outcomes of OS, DFS, local recurrence, distant
recurrence and breast-cancer-specific survival because these are
the main endpoints used in clinical trials. Besides, we performed
subgroup analyses according to hormone receptor and HER2
status as well as triple negativity.
Methods
Identification of randomized studies
Two investigators (YW Jiang and WJ Yin) independently
obtained relevant English language articles through searches of
PubMed, EBSCO and Web of Science databases, conference
proceedings (American Society of Clinical Oncology, San Antonio
Breast Cancer Symposium and European Society for Medical
Oncology) and scanned the reference lists of key trials and review
articles from 1998 (based on the first reported trial of capecitabine
efficacy in humans) to the end of November 2011. PubMed,
EBSCO and Web of Science databases were searched using terms
‘capecitabine’, ‘Xeloda’, and the exploded MeSH term ‘breast
neoplasms’. We searched conference proceedings through online
websites at www.asco.org, www.esmo.org and www.sabcs.org. We
included randomized, open-label, phase III trials in early breast
cancer. We excluded trials if they compared the efficacy of
capecitabine-based regimens in the salvage and neoadjuvant
setting, as well as those to test the efficacy of single capecitabine
in the adjuvant setting.
Study endpoints
In this meta-analysis, the primary outcome was DFS, defined as
time from randomization to the first occurrence of disease
progression or death from any cause without documentation of
a cancer-related event. Secondary outcomes included overall
survival (death from any cause), time to distant recurrence, breast-
cancer-specific survival (death from breast cancer) and time to
death from other causes.
Data extraction
From each eligible trial, two independent reviewers (YW Jiang
and WJ Yin) extracted data, including authors’ names, journal,
year of publication, trial design, patient eligibility, baseline patient
characteristics, dosing regimens, duration of follow-up, and
treatment changes due to toxicity. For trials that compared
different types of treatment, we derived the number of patients
with any recurrence or any death and the total number of patients
in each treatment arm. We also derived HRs and 95% CIs for the
outcomes OS and DFS, or evaluated the logarithm of the HR for
death. All of the outcomes were based on the intention-to-treat
(ITT) analysis. If the trial results were reported in multiple
publications, we extracted the most recently reported endpoints.
Statistical analysis
HR was used to evaluate the efficacy of a taxane–anthracycline
regimen and a taxane–anthracycline–capecitabine regimen in
early breast cancer. For each study, the between-study heteroge-
neity was assessed by the x
2 based Q statistics and I
2 test.
Heterogeneity was considered as either P,0.50 or I
2.50%. All of
the data from each study used either fixed effects (Mantel–
Haenszel’s method) or random-effects (DerSimonian and Laird’s
method) models according to the heterogeneity result. If there was
no between-study heterogeneity, the two methods provided similar
results. Funnel plots and Begger’s test were used to test the possible
publication bias. Sensitivity analyses were performed to evaluate
the influence of individual studies on the summary effect. In the
subgroup analysis, statistical analysis was performed in different
hormone receptor status, HER2 status and triple negative status.
All of the analyses were performed by Stata 10.0 software (Stata
Corporation, College Station, TX, USA), using two-sided P
values.
Results
Eligible studies
Based on the search strategy, two studies were selected. The two
trials enrolled 4107 breast cancer patients, of whom 2058 received
a taxane–anthracycline–capecitabine-containing regimen and
2049 received a taxane–anthracycline-based regimen. All of the
patients were histologically confirmed as having invasive breast
cancer. These two studies had study population and trial design in
common. The study details are shown in Table 1.
Meta-analysis of the primary endpoint
There was no between-study heterogeneity in DFS (heteroge-
neity x
2=0.10 (d.f.=1), I
2=0.0%, P=0.747). Therefore, we used
the fixed-effect model to analyze the data and found that DFS was
significantly improved in the capecitabine arm versus the controls
(HR=0.83, 95% CI: 0.71–0.98; P=0.027) (figure 1).
Meta-analysis of the secondary endpoints
There was no between-study heterogeneity in HRs of the studies
(heterogeneity x
2=0.09 (d.f.=1), I
2=0.0%, P=0.764) and the
addition of capecitabine to standard treatment showed improve-
ment in OS (HR=0.71, 95% CI: 0.57–0.88; P=0.002) (figure 2).
For the distant recurrence, through the fixed-effect model
(heterogeneity x
2=0.02 (d.f.=1), I
2=0.0%, P=0.897), we also
observed a significant improvement in favor of the capecitabine-
based arm (HR=0.79, 95% CI: 0.66–0.94; P=0.008) (figure 3).
We used the fixed-effect model (heterogeneity x
2=0?00 (d.f.=1),
I
2=0.0%, P=0.983) to analyze the breast-cancer-specific survival,
and found that there was a significant difference between the two
arms (HR=0.65, 95% CI: 0.51–0.83, P=0.001) (figure 4).
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between patients with and without the addition of capecitabine
(heterogeneity x
2=0.31 (d.f.=1), I
2=0.0%, P=0.576; HR=
1.07, 95% CI: 0.63–1.82, P=0.798).
Subgroup analysis
For the subgroup analysis, we divided them into triple
negative breast cancer patients and non-triple negative breast
cancer patients. From the analysis, we found that capecitabine
improved DFS in triple negative patients (HR=0.71, 95% CI:
0.53–0.96, P=0.028), by fixed method (figure 5). For the
different hormone receptor status, no significant difference was
found between the groups in hormone receptor positive patients
(HR=0.90, CI: 0.71–1.13, P=0.348), but we exactly found the
difference between the groups in hormone receptor negative
patients (HR=0.73, CI: 0.56–0.94, P=0.017) (figure 6).The
association between DFS and HER2 status were not statistically
significant in HER2 positive patients (HR=0.87, CI: 0.57–1.33,
P=0.516), but revealed a significant difference in HER2
negative counterparts (HR=0.81, CI: 0.67–0.98, P=0.034)
(figure 7).
Publication bias and sensitivity analyses
We performed the funnel plots and Begger’s test to assess the
publication bias. As a result, there was no publication bias in each
test (z=21.00, P=0.317) for the primary endpoint analysis and
the secondary endpoint analysis (data not shown). The influence of
individual studies on the summary effect estimate was performed
by sensitivity analyses on the overall HR. No individual study
affected the overall HR, because omission of any single study
made no significant difference.
Discussion
This meta-analysis aimed to assess the efficacy of addition of
capecitabine to anthracycline–taxane-based adjuvant therapy in
high-risk early breast cancer for the first time. First, it was
reasonable to merge these two large clinical trials because of their
similar regimens for control (anthracycline–taxane-based poly-
chemotherapy) and experiment arm (anthracycline–taxane–cape-
citabine-based polychemotherapy). Second, capecitabine in com-
bination with docetaxel is synergic and effective and is indicated
for treatment of metastatic breast cancer [12]. Therefore, it may
Table 1. Characteristics of studies included for the meta-analysis.
study patients treatment Cycles Duration of follow-up
per treatment arm
USO 1304 Epirubicin+Cyclophosphamide q3w 4 5 years
Docetaxel q3w 4
1307 Epirubicin+Cyclophosphamide q3w 4
Docetaxel+Capecitabine q3w 4
FinXX 745 Docetaxel q3w 3 5 years
+Epirubicin+Cyclophosphamide+5- fluorouracil q3w 3
751 Docetaxel++Capecitabine q3w 3
+Epirubicin+Cyclophosphamide+5- fluorouracil+Capecitabine q3w 3
doi:10.1371/journal.pone.0032474.t001
Figure 1. Forest plot of meta-analysis on the disease-free survival for the addition of capecitabine to standard treatment.
doi:10.1371/journal.pone.0032474.g001
Capecitabine Adjuvant Therapy in Breast Cancer
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32474also improve prognosis of adjuvant therapy. The present meta-
analysis does demonstrate the clinical benefits of addition of
capecitabine to polychemotherapy.
Many trials, such as PACS01 and NSABP B28, have
demonstrated that taxane-containing regimens improve DFS and
OS in an adjuvant treatment for breast cancer patients [13].
Capecitabine is a prodrug that is enzymatically metabolized in the
liver to fluorouracil, and it eventually inhibits DNA synthesis and
function. On the other hand, its synergistic effect with docetaxel
and other cytotoxic drugs can be attributed to an increase in TP
level in the tumors [14,15]. The control regimens of the USON
01062 (AC-T) and Finxx (T-CEF) trials may be similar in efficacy,
although the efficacy of the T-CEF regimen is still under
investigation. These two large trials failed to provide a satisfactory
outcome, but from the current meta-analysis, we found that
capecitabine plus standard chemotherapy significantly improved
OS, DFS, local recurrence, distant recurrence, and breast-cancer-
specific survival. Due to the synergistic effect of taxane and
capecitabine, taxane–anthracylcine-based regimens with capecita-
bine may effectively inhibit distant micrometastases, to further
improve the efficacy, and could be a novel combination
chemotherapy regimen. A previous study showed that adjuvant
capecitabine monotherapy is not superior to CMF administered
every 3 weeks. However, combination regimens with capecitabine
may provide benefits over single-agent therapy because the
combined regimen enhances the control of metastatic foci [16].
Our meta-analysis provides the efficacy of capecitabine to some
subtypes of early breast cancer patients, such as hormone receptor
negative, HER2 negative and triple negative cancers. This was
also showed in ABCSG-24 trial that addition of capecitabine to
epirubicin plus docetaxel is associated with a greater chance of
achieving pCR when the cancer is hormone receptor negative
Figure 2. Forest plot of meta-analysis on the overall survival for the addition of capecitabine to standard treatment.
doi:10.1371/journal.pone.0032474.g002
Figure 3. Forest plot of meta-analysis on the distant recurrence for the addition of capecitabine to standard treatment.
doi:10.1371/journal.pone.0032474.g003
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interactions of capecitabine with other chemotherapy agents,
especially in some biologic shugroups of early breast cancer. Triple
negative patients have an absence of estrogen receptor, proges-
terone receptor and HER2/neu expression, and have worse
prognosis [18,19]. Furthermore, there is no standard adjuvant
treatment for this category of patient [20]. Some trials have
provided a clue for the striking effect of taxane-containing
polychemotherapy in improving breast cancer in triple negative
patients [21,22,23]. However, our meta-analysis suggests that
addition of capecitabine to anthracycline–taxane-based polyche-
motherapy is better than anthracycline–taxane-based polyche-
motherapy, and therefore, might be one of the good regimens for
adjuvant therapy of triple negative breast cancer.
Capecitabine is an oral, tumor-targeted drug. From previous
trials, we have found fewer adverse reactions with docetaxel and
capecitabine compared with anthracycline or paclitaxel [7,24,25].
To some extent, addition of capecitabine did not significantly
increase the toxicity, except for diarrhea and hand–foot syndrome
related to capecitabine, but it might have reduced neutropenia and
febrile neutropenia, which could have been due to reduced dose of
docetaxel [3].
There were some limitations to our meta-analysis. Only two
trials were included in this analysis. Fortunately, all encouraging
results were yielded in the ITT analysis, which provides powerful
evidence to support capecitabine-based polychemotherapy as a
good candidate regimen for adjuvant therapy of early breast
cancer. We are looking forward for more clinical trials to perfect
this hypothesis. However, the two trials were very similar, and
therefore this meta-analysis might be highly persuasive.
Above all, the results of the current meta-analysis indicate that
taxane-based regimens with capecitabine may be effective,
Figure 4. Forest plot of meta-analysis on the breast cancer specific survival for the addition of capecitabine to standard treatment.
doi:10.1371/journal.pone.0032474.g004
Figure 5. Forest plot of meta-analysis on the disease-free survival in triple negative patients for the addition of capecitabine to
standard treatment.
doi:10.1371/journal.pone.0032474.g005
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doi:10.1371/journal.pone.0032474.g006
Figure 7. Forest plot of meta-analysis on the disease-free survival in HER2 positive and negative patients for the addition of
capecitabine to standard treatment.
doi:10.1371/journal.pone.0032474.g007
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especially in triple negative patients.
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